PLEURAL DISEASES MARKET ANALYSIS

Pleural Diseases MarketSize and Trends

The Global Pleural Diseases Market size was valued at US$ 5.01 Bn in 2023 and is expected to reach US$ 8.13 Bn by 2030, growing at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030.

The global pleural diseases market refers to the market for diagnosing, treating, and managing diseases and conditions related to the pleura, the membrane that covers the lungs and lines the chest cavity. Pleural diseases encompass a range of conditions such as pleurisy, pleural effusion, pneumothorax, mesothelioma, and others. These diseases can cause symptoms like chest pain, difficulty breathing, coughing, and fluid accumulation in the pleural space. The market includes various diagnostic tools, imaging techniques, therapeutic interventions, and supportive care measures aimed at improving patient outcomes and the quality of life. With advancements in medical technology, imaging modalities, and treatment approaches, the global pleural diseases market continues to evolve to provide better diagnostic accuracy, more targeted treatments, and improved patient care.

• Increasing Focus on Minimally Invasive Procedures: There is a growing trend towards minimally invasive procedures in the management of global pleural diseases. Minimally invasive interventions, such as thoracoscopy and pleuroscopy, offer advantages such as reduced trauma, shorter hospital stays, and faster recovery times compared to traditional open surgeries. This trend is driven by the desire to improve patient outcomes, enhance patient comfort, and minimize healthcare costs.
• Rising Adoption of Molecular Diagnostics: Molecular diagnostic techniques are gaining traction in the Global Pleural Diseases market. These techniques allow for the detection of specific biomarkers, genetic mutations, and molecular alterations associated with global pleural diseases. The use of molecular diagnostics facilitates early detection, precise diagnosis, prognostic assessments, and personalized treatment strategies. The increasing availability and affordability of molecular diagnostic tools contribute to their growing adoption in the market. For instance, on September 12, 2023, researchers reported at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, that the newly identified biomarkers in mesothelioma patients' exhaled breath may be useful in predicting if they are likely to respond to treatment.
• Emphasis on Multidisciplinary Collaboration: There is a growing recognition of the importance of multidisciplinary collaboration in the management of global pleural diseases. Multidisciplinary teams consisting of pulmonologists, thoracic surgeons, radiologists, pathologists, and other healthcare professionals work together to ensure comprehensive care for patients. This collaborative approach facilitates accurate diagnosis, optimal treatment planning, and shared decision-making, leading to improved patient outcomes.
• Integration of Digital Health Technologies: Digital health technologies are being integrated into the Global Pleural Diseases market to improve patient care and management. Telemedicine, remote monitoring, and mobile applications allow for remote consultations, real-time patient monitoring, and data collection. These technologies enable healthcare providers to deliver personalized care, monitor disease progression, and enhance patient engagement. The COVID-19 pandemic has further accelerated the adoption of digital health solutions in the global pleural diseases market.